Design Source Inc (NVIV) 0.6800 $NVIV
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against InVivo Therapeutics Holdings Corp. and Its Board of Directors and a Lead Plaintiff Deadline of October 6, 2014 -- NVIV
GlobeNewswire - Wed Sep 10, 4:24PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(OTC:NVIV) securities between April 5, 2013 and August 26, 2013.
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Thu Sep 04, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in InVivo Therapeutics Holdings Corp. to Contact the Firm Before the October 6, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- NVIV
GlobeNewswire - Tue Sep 02, 1:08PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court of Massachusetts on behalf of purchasers of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (Other OTC:NVIV) common stock during the period between April 5, 2013 through August 26, 2013, inclusive (the "Class Period" .
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In InVivo Therapeutics Holdings Corp. (NVIV) To Contact The Firm
PR Newswire - Fri Aug 29, 8:15PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (OTC: NVIV) of the October 6, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against InVivo and certain executives.
InVivo Therapeutics to Present at 2014 Aegis Healthcare Conference
Business Wire - Tue Aug 26, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) announced today that Mark Perrin, Chief Executive Officer, is scheduled to present at the 2014 Aegis Healthcare Conference to be held September 10-13, 2014 at The Encore at Wynn Las Vegas. The Company's presentation will be on Thursday, September 11th at 10:00 a.m. PDT.
UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving InVivo Therapeutics Holdings Corp. and a Lead Plaintiff Deadline of October 6, 2014 -- NVIV
GlobeNewswire - Mon Aug 25, 6:02PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (OTC:NVIV) common stock between April 5, 2013 and August 26, 2013.
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against InVivo Therapeutics Holdings Corp.
Business Wire - Mon Aug 25, 9:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (OTC:NVIV) that all purchasers of InVivo securities between April 5, 2013 and August 26, 2013, inclusive (the "Class Period" , have until October 6, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in InVivo Therapeutics Holdings Corp. (NVIV) to Contact the Firm
Marketwire - Sat Aug 23, 8:15AM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (OTCQB: NVIV) of the October 6, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against InVivo and certain executives.
InVivo Therapeutics to Present at the Stem Cell Meeting on the Mesa
Business Wire - Thu Aug 21, 7:01AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) announced today that Tom Ulich, MD, InVivo's Chief Scientific Officer, will present at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.
INVESTOR ALERT: Class Action Lawsuit Against InVivo Therapeutics Holdings Corp. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Aug 19, 9:32AM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of purchasers of the securities of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (OTC:NVIV) between April 5, 2013 and August 26, 2013, inclusive (the "Class Period" .
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In InVivo Therapeutics Holdings Corp. To Contact The Firm Before The October 6, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Mon Aug 18, 12:49PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court of Massachusetts on behalf of purchasers of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (Other OTC: NVIV) common stock during the period between April 5, 2013 through August 26, 2013, inclusive (the "Class Period" .
InVivo Therapeutics to Present at 16th Annual Rodman & Renshaw Healthcare Conference
Business Wire - Mon Aug 18, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, InVivo's Chief Executive Officer, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Wednesday, September 10th at 9:10AM ET. A live webcast will be available at http://wsw.com/webcast/rrshq24/nviv.
Shapiro Haber & Urmy LLP Announces It Filed the Securities Fraud Class Action Lawsuit Against InVivo Therapeutics Holdings Corp.
Business Wire - Fri Aug 15, 5:22PM CDT
The Boston, MA law firm Shapiro Haber & Urmy LLP filed the class action securities fraud suit against InVivo Therapeutics Holdings Corp. ("InVivo" (OTCBB: NVIV), a Cambridge, MA company, and its former Chairman and CEO for violations of federal securities laws on July 31, 2014. The firm filed the complaint in the United States District Court for the District of Massachusetts, entitled Battle Construction Co., Inc. v. InVivo Therapeutics Holdings Corp., et al., C.A. No. 14-cv-13180.
SHAREHOLDER ALERT: Investigation on Behalf of InVivo Therapeutics Holdings Corp. Investors Announced by Law Offices of Howard G. Smith
Business Wire - Mon Aug 11, 9:32AM CDT
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (OTC:NVIV). The investigation concerns possible violations of federal securities laws and focuses on statements issued by InVivo concerning the Company's operations and financial prospects.
InVivo Therapeutics awarded US patent Notice of Allowance for Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells
M2 - Mon Aug 11, 8:03AM CDT
Biotechnology company InVivo Therapeutics Holdings (Other OTC:NVIV) reported on Monday the receipt of Notice of Allowance from the US Patent and Trademark Office (USPTO) for "Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries."
InVivo Therapeutics Receives Notice of Allowance on Patent Covering Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells
Business Wire - Mon Aug 11, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/177,888, titled "Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries". The application covers InVivo's Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial, and its Neuro-Spinal Scaffold combined with stem cells, which is being developed for the treatment of chronic spinal cord injury. InVivo is the exclusive licensee of this intellectual property for spinal cord injury and other indications through a license with Boston Children's Hospital and the Massachusetts Institute of Technology (MIT). A notice of allowance from the USPTO is a written notification that a patent application has cleared internal review and is pending issuance.
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against InVivo Therapeutics Holdings Corp. and Its Board of Directors and a Lead Plaintiff Deadline of October 6, 2014 -- NVIV
GlobeNewswire - Fri Aug 08, 8:38AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (OTC:NVIV) securities between April 5, 2013 and August 26, 2013.
Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit on Behalf of InVivo Therapeutics Holdings Co. Investors Has Been Filed in the United States District Court for the District of Massachusetts -- NVIV
GlobeNewswire - Thu Aug 07, 12:15PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of InVivo Therapeutics Holdings Co. ("InVivo" or the "Company" (OTC:NVIV) securities between April 5, 2013 through August 26, 2013, inclusive (the "Class Period" .
Investigation on Behalf of InVivo Therapeutics Holdings Corp. Investors Announced by Kirby McInerney LLP
Business Wire - Wed Aug 06, 3:39PM CDT
Kirby McInerney LLP announced today that a class action lawsuit is pending in the United States District Court for the District of Massachusetts on behalf of investors who acquired InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (OTC:NVIV) securities during the period from April 5, 2013 through August 26, 2013 (the "class period" . Pursuant to applicable law, investors have until October 6, 2014 to file a motion to be appointed as lead plaintiff in the investor lawsuit.
InVivo Therapeutics Reports 2014 Second Quarter Financial Results and Business Update
Business Wire - Wed Aug 06, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended June 30, 2014.
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against InVivo Therapeutics Holdings Corp. and Its Board of Directors and a Lead Plaintiff Deadline of October 6, 2014 -- NVIV
GlobeNewswire - Wed Sep 10, 4:24PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(OTC:NVIV) securities between April 5, 2013 and August 26, 2013. Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Thu Sep 04, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in InVivo Therapeutics Holdings Corp. to Contact the Firm Before the October 6, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- NVIV
GlobeNewswire - Tue Sep 02, 1:08PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court of Massachusetts on behalf of purchasers of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(Other OTC:NVIV) common stock during the period between April 5, 2013 through August 26, 2013, inclusive (the "Class Period" . Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In InVivo Therapeutics Holdings Corp. (NVIV) To Contact The Firm
PR Newswire - Fri Aug 29, 8:15PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(OTC: NVIV) of the October 6, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against InVivo and certain executives. InVivo Therapeutics to Present at 2014 Aegis Healthcare Conference
Business Wire - Tue Aug 26, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) announced today that Mark Perrin, Chief Executive Officer, is scheduled to present at the 2014 Aegis Healthcare Conference to be held September 10-13, 2014 at The Encore at Wynn Las Vegas. The Company's presentation will be on Thursday, September 11th at 10:00 a.m. PDT.
UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving InVivo Therapeutics Holdings Corp. and a Lead Plaintiff Deadline of October 6, 2014 -- NVIV
GlobeNewswire - Mon Aug 25, 6:02PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(OTC:NVIV) common stock between April 5, 2013 and August 26, 2013. INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against InVivo Therapeutics Holdings Corp.
Business Wire - Mon Aug 25, 9:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(OTC:NVIV) that all purchasers of InVivo securities between April 5, 2013 and August 26, 2013, inclusive (the "Class Period" , have until October 6, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in InVivo Therapeutics Holdings Corp. (NVIV) to Contact the Firm
Marketwire - Sat Aug 23, 8:15AM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(OTCQB: NVIV) of the October 6, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against InVivo and certain executives. InVivo Therapeutics to Present at the Stem Cell Meeting on the Mesa
Business Wire - Thu Aug 21, 7:01AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) announced today that Tom Ulich, MD, InVivo's Chief Scientific Officer, will present at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.
INVESTOR ALERT: Class Action Lawsuit Against InVivo Therapeutics Holdings Corp. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Aug 19, 9:32AM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of purchasers of the securities of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(OTC:NVIV) between April 5, 2013 and August 26, 2013, inclusive (the "Class Period" . SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In InVivo Therapeutics Holdings Corp. To Contact The Firm Before The October 6, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Mon Aug 18, 12:49PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court of Massachusetts on behalf of purchasers of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(Other OTC: NVIV) common stock during the period between April 5, 2013 through August 26, 2013, inclusive (the "Class Period" . InVivo Therapeutics to Present at 16th Annual Rodman & Renshaw Healthcare Conference
Business Wire - Mon Aug 18, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, InVivo's Chief Executive Officer, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Wednesday, September 10th at 9:10AM ET. A live webcast will be available at http://wsw.com/webcast/rrshq24/nviv.
Shapiro Haber & Urmy LLP Announces It Filed the Securities Fraud Class Action Lawsuit Against InVivo Therapeutics Holdings Corp.
Business Wire - Fri Aug 15, 5:22PM CDT
The Boston, MA law firm Shapiro Haber & Urmy LLP filed the class action securities fraud suit against InVivo Therapeutics Holdings Corp. ("InVivo"
(OTCBB: NVIV), a Cambridge, MA company, and its former Chairman and CEO for violations of federal securities laws on July 31, 2014. The firm filed the complaint in the United States District Court for the District of Massachusetts, entitled Battle Construction Co., Inc. v. InVivo Therapeutics Holdings Corp., et al., C.A. No. 14-cv-13180. SHAREHOLDER ALERT: Investigation on Behalf of InVivo Therapeutics Holdings Corp. Investors Announced by Law Offices of Howard G. Smith
Business Wire - Mon Aug 11, 9:32AM CDT
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(OTC:NVIV). The investigation concerns possible violations of federal securities laws and focuses on statements issued by InVivo concerning the Company's operations and financial prospects. InVivo Therapeutics awarded US patent Notice of Allowance for Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells
M2 - Mon Aug 11, 8:03AM CDT
Biotechnology company InVivo Therapeutics Holdings (Other OTC:NVIV) reported on Monday the receipt of Notice of Allowance from the US Patent and Trademark Office (USPTO) for "Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries."
InVivo Therapeutics Receives Notice of Allowance on Patent Covering Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells
Business Wire - Mon Aug 11, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/177,888, titled "Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries". The application covers InVivo's Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial, and its Neuro-Spinal Scaffold combined with stem cells, which is being developed for the treatment of chronic spinal cord injury. InVivo is the exclusive licensee of this intellectual property for spinal cord injury and other indications through a license with Boston Children's Hospital and the Massachusetts Institute of Technology (MIT). A notice of allowance from the USPTO is a written notification that a patent application has cleared internal review and is pending issuance.
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against InVivo Therapeutics Holdings Corp. and Its Board of Directors and a Lead Plaintiff Deadline of October 6, 2014 -- NVIV
GlobeNewswire - Fri Aug 08, 8:38AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(OTC:NVIV) securities between April 5, 2013 and August 26, 2013. Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit on Behalf of InVivo Therapeutics Holdings Co. Investors Has Been Filed in the United States District Court for the District of Massachusetts -- NVIV
GlobeNewswire - Thu Aug 07, 12:15PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of InVivo Therapeutics Holdings Co. ("InVivo" or the "Company"
(OTC:NVIV) securities between April 5, 2013 through August 26, 2013, inclusive (the "Class Period" . Investigation on Behalf of InVivo Therapeutics Holdings Corp. Investors Announced by Kirby McInerney LLP
Business Wire - Wed Aug 06, 3:39PM CDT
Kirby McInerney LLP announced today that a class action lawsuit is pending in the United States District Court for the District of Massachusetts on behalf of investors who acquired InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company"
(OTC:NVIV) securities during the period from April 5, 2013 through August 26, 2013 (the "class period" . Pursuant to applicable law, investors have until October 6, 2014 to file a motion to be appointed as lead plaintiff in the investor lawsuit. InVivo Therapeutics Reports 2014 Second Quarter Financial Results and Business Update
Business Wire - Wed Aug 06, 3:30PM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended June 30, 2014.
